We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+24.49%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.63B
AUM Growth
+$415M
Cap. Flow
+$332K
Cap. Flow %
0.01%
Top 10 Hldgs %
37.9%
Holding
228
New
11
Increased
45
Reduced
33
Closed
6

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$17M
2
UNH icon
UnitedHealth
UNH
+$15.3M
3
CVS icon
CVS Health
CVS
+$14M
4
MRNA icon
Moderna
MRNA
+$13.1M
5
EXEL icon
Exelixis
EXEL
+$9.71M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$29.8M
2
AGN
Allergan plc
AGN
+$28M
3
GILD icon
Gilead Sciences
GILD
+$23.5M
4
ILMN icon
Illumina
ILMN
+$16.8M
5
CI icon
Cigna
CI
+$11.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.26%
2 Real Estate 2.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
26
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$22.8M 0.87%
410,153
+10,896
+3% +$466K
BSX icon
27
Boston Scientific
BSX
$68.4B
$22.6M 0.86%
644,935
+57,273
+10% +$2.06M
SRPT icon
28
Sarepta Therapeutics
SRPT
$1.64B
$22.5M 0.86%
140,129
– –
EXEL icon
29
Exelixis
EXEL
$14.1B
$22.2M 0.84%
933,949
+418,824
+81% +$9.71M
ISRG icon
30
Intuitive Surgical
ISRG
$126B
$19M 0.72%
100,017
-2,100
-2% -$376K
HUM icon
31
Humana
HUM
$44B
$18.8M 0.72%
48,506
+2,376
+5% +$889K
ALNY icon
32
Alnylam Pharmaceuticals
ALNY
$27.4B
$18.6M 0.71%
125,867
-11,750
-9% -$1.58M
BDX icon
33
Becton Dickinson
BDX
$45.6B
$18.6M 0.71%
79,698
– –
CNC icon
34
Centene
CNC
$30.1B
$18.3M 0.7%
288,194
– –
IMMU
35
DELISTED
Immunomedics Inc
IMMU
$17.6M 0.67%
497,103
+10,000
+2% +$292K
SNY icon
36
Sanofi
SNY
$103B
$16.7M 0.64%
327,367
– –
MCK icon
37
McKesson
MCK
$101B
$16.5M 0.63%
107,537
+48,012
+81% +$6.93M
VTRS icon
38
Viatris
VTRS
$20.7B
$16.3M 0.62%
1,010,754
– –
CI icon
39
Cigna
CI
$76.1B
$15M 0.57%
79,988
-62,667
-44% -$11.9M
NVS icon
40
Novartis
NVS
$301B
$14.9M 0.57%
171,008
-8,839
-5% -$763K
ONC
41
BeOne Medicines Ltd
ONC
$33.4B
$14.1M 0.54%
74,984
– –
EW icon
42
Edwards Lifesciences
EW
$50B
$14M 0.53%
202,146
– –
PRAH
43
DELISTED
PRA Health Sciences, Inc.
PRAH
$14M 0.53%
143,508
– –
TECH icon
44
Bio-Techne
TECH
$11.2B
$13.7M 0.52%
206,840
-23,924
-10% -$1.43M
AZN icon
45
AstraZeneca
AZN
$266B
$12.4M 0.47%
117,399
-20,650
-15% -$2.13M
IDXX icon
46
Idexx Laboratories
IDXX
$44.1B
$12.2M 0.47%
37,014
-3,300
-8% -$955K
ACAD icon
47
Acadia Pharmaceuticals
ACAD
$4.55B
$12.2M 0.46%
250,743
+29,144
+13% +$1.4M
IQV icon
48
IQVIA
IQV
$39.1B
$11.7M 0.44%
82,266
– –
IONS icon
49
Ionis Pharmaceuticals
IONS
$8.81B
$11.4M 0.43%
193,201
– –
ZBH icon
50
Zimmer Biomet
ZBH
$18.4B
$11.3M 0.43%
97,493
+16,980
+21% +$1.96M
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Tekla Capital Management held 228 positions worth $2.63B, up 19% from $2.21B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Tekla Capital Management's Q2 2020 filing shows 11 new, 45 increased, 33 reduced and 6 closed positions. Its largest new stake was Molina Healthcare: 27,536 shares worth $4.9M. The largest sale was Biogen, an estimated $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2020 buy was Molina Healthcare: 27,536 shares worth $4.9M.
  • Tekla Capital Management added most to AbbVie in Q2 2020, an estimated $17M increase.
  • Tekla Capital Management's biggest Q2 2020 reduction was Biogen, cutting an estimated $29.8M.
  • Tekla Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $28M.
  • Tekla Capital Management's ten largest holdings make up 38% of its $2.63B portfolio in Q2 2020.
  • Tekla Capital Management opened 11 new positions and closed 6 in Q2 2020.
  • Tekla Capital Management's portfolio value rose 19% quarter-over-quarter to $2.63B.

Based on Tekla Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.